Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

477 patients suspected of acute myocardial infarction, with onset of less than 12 hours, were randomised to a control group or a group receiving intravenous atenolol followed by oral treatment for 10 days. In patients with electrocardiographic (ECG) changes of infarction at entry, intravenous atenolol significantly reduced enzyme release by one- third and enhanced R wave preservation. In patients without ECG changes of infarction at entry, treatment significantly prevented the development of infarction in a proportion of patients. There was also a significant reduction in R- on- T ectopics, repetitive ventricular arrhythmias and supraventricular arrhythmias. Treated patients had greater pain relief and required less opiate analgesics. Fewer atenolol- treated patients died at 1 week, had non- fatal cardiac arrests, developed heart failure, or suffered reinfarction. © 1983, ADIS Press Australasia Pty Ltd (Inc. NSW). All rights reserved.

Original publication




Journal article



Publication Date





303 - 307